Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LP-98

Phase 2Small molecule

SShanxi Kangbao Biological Product Co., Ltd.

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV-Infected IndividualsRecruiting

HIV-Infected IndividualsPhase 2

Recruiting

Timeline

Expected Milestones

Q3 2026

Phase 1/2Recruiting

HIV-Infected Individuals

NCT07433387

Clinical

Trials by Indication[1]

HIV-Infected Individuals1 trial

Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals

Recruiting·SShanxi Kangbao Biological Product Co., Ltd.·Phase 1/2·NCT07433387·30 enrolled

Immunogenicity1 trial

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects

Completed·SShanxi Kangbao Biological Product Co., Ltd.·Phase 1·NCT05933824·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LP-98. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LP-98 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LP-98. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanxi Kangbao Biological Product Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanxi Kangbao Biological Product Co., Ltd.

Related News